

**Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab**

Hagström, Emil; Steg, P. Gabriel; Szarek, Michael; Bhatt, Deepak L.; Bittner, Vera A.; Danchin, Nicolas; Diaz, Rafael; Goodman, Shaun G.; Harrington, Robert A.; Jukema, J. Wouter; Liberopoulos, Evangelos; Marx, Nikolaus; **Viigimaa, Margus** Circulation 2022 / p. 657 - 672 <https://doi.org/10.1161/CIRCULATIONAHA.121.057807> [Journal metrics at Scopus](#) [Article at Scopus](#) [Journal metrics at WOS](#) [Article at WOS](#)

**Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol**

Schwartz, Gregory G.; Szarek, Michael; Bittner, Vera A.; Diaz, Rafael; Goodman, Shaun G.; **Viigimaa, Margus** Journal of the American College of Cardiology 2021 / p. 421–433 : ill <https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102> <https://doi.org/10.1016/j.jacc.2021.04.102>

**2022: The year in cardiovascular disease - the year of upfront lipid lowering combination therapy**

**Banach, Maciej; Reiner, Zeljko**; Cicero, Arrigo F.G.; Sabouret, Pierre; **Viigimaa, Margus**; Sahebkar, Amirhossein; Postadzhiyan, Arman; Gaita, Dan; Pella, Daniel; Penson, Peter E. Archives of Medical Science 2022 / p. 1429-1434 : ill <https://doi.org/10.5114/aoms/156147> [Journal metrics at Scopus](#) [Article at Scopus](#) [Journal metrics at WOS](#) [Article at WOS](#)